Content about Eli Lilly & Co.

July 9, 2012
FDA approves Lilly, BMS drug for KRAS wild-type colorectal cancer

The Food and Drug Administration has approved a drug made by Eli Lilly and Bristol-Myers Squibb for treating a form of colorectal cancer, the two companies said.

NEW YORK — The Food and Drug Administration has approved a drug made by Eli Lilly and Bristol-Myers Squibb for treating a form of colorectal cancer, the two companies said.

Lilly and Bristol announced the approval of Erbitux (cetuximab) for treating colorectal cancer that is KRAS mutation-negative, expresses the epidermal growth factor receptor and has spread to other parts of the body, also known as metastasis. The drug is approved for use alongside a chemotherapy combination containing irinotecan, 5-fluorouracil and leucovorin, also known as FOLFIRI.

April 13, 2012
Lilly chief executive John Lechleiter appointed as PhRMA chairman

The Pharmaceutical Research and Manufacturers of America announced Friday the appointment of Eli Lilly chairman, president and CEO John Lechleiter as PhRMA chairman at its annual meeting.

BOSTON — The Pharmaceutical Research and Manufacturers of America announced Friday the appointment of Eli Lilly chairman, president and CEO John Lechleiter as PhRMA chairman at its annual meeting. The group also elected Celgene president and CEO Robert Hugin as chairman-elect of its board of directors and Pfizer president and CEO Ian Read as board treasurer. Lechleiter replaces Sanofi CEO Christopher Viehbacher as chairman.

March 7, 2012
Diabetes drug from Lilly, BI hits shelves

A new drug for Type 2 diabetes made by Eli Lilly and Boehringer Ingelheim is available in pharmacies, the companies said Wednesday.

INDIANAPOLIS — A new drug for Type 2 diabetes made by Eli Lilly and Boehringer Ingelheim is available in pharmacies, the companies said Wednesday.

The two companies announced the availability of Jentadueto (linagliptin and metformin hydrochloride). The Food and Drug Administration approved the drug on Jan. 30.

February 3, 2012
New diabetes drug launches show primary care market still strong

For all the fears about the patent cliff, at least one disease state seems to be on the up-and-up in terms of new drug development and new products.

WHAT IT MEANS AND WHY IT'S IMPORTANT — For all the fears about the patent cliff, at least one disease state seems to be on the up-and-up in terms of new drug development and new products.

(THE NEWS: FDA approves Bydureon. For the full story, click here.)

January 31, 2012
FDA approves Lilly-Boehringer Ingelheim diabetes drug

The Food and Drug Administration has approved a new treatment for Type 2 diabetes made by Eli Lilly and Boehringer Ingelheim, the drug makers said.

INDIANAPOLIS — The Food and Drug Administration has approved a new treatment for Type 2 diabetes made by Eli Lilly and Boehringer Ingelheim, the drug makers said.

The FDA approved Jentadueto (linagliptin and metformin) tablets, designed to be taken twice daily. The approval marks the second since the two companies announced their collaboration to develop diabetes drugs in January 2011; the first drug approved under the Lilly-BI partnership was Tradjenta (linagliptin), approved in May 2011.

December 9, 2011
Lilly expands Spanish-language section of 'Lilly for Better Health' Web portal

Drug maker Eli Lilly has expanded its Spanish-language portal, the company said Friday.

INDIANAPOLIS — Drug maker Eli Lilly has expanded its Spanish-language portal, the company said Friday.

Subsidiary Lilly USA launched an expanded "En Español" section of the Lilly For Better Health website. The section features a 60-page interactive health album that provides tips on healthy eating, physical activity and managing health conditions, as well as health-and-wellness quizzes and risk assessments on weight management, diabetes and other topics.

December 8, 2011
Eli Lilly, Boehringer Ingelheim announce linagliptin trial results

A drug currently under clinical development for Type 2 diabetes produced "meaningful" reductions in blood sugar, according to results of a late-stage clinical study.

INDIANAPOLIS — A drug currently under clinical development for Type 2 diabetes produced "meaningful" reductions in blood sugar, according to results of a late-stage clinical study.

Eli Lilly & Co. and Boehringer Ingelheim announced results of a 24-week, open-label arm of a phase-3 study of the investigational drug linagliptin combined with the generic drug metformin, presenting results at the International Diabetes Federation World Diabetes Conference in Dubai.

November 17, 2011
Lilly donates $4 million for tuberculosis drug discovery

Drug maker Eli Lilly is donating more than $4 million to the Infectious Disease Research Institute, the company said Thursday.

SEATTLE — Drug maker Eli Lilly is donating more than $4 million to the Infectious Disease Research Institute, the company said Thursday.

The company said the funding, which brings its total donations to IDRI to more than $20 million and its total funding for anti-tuberculosis efforts to more than $170 million, will support early-phase drug discovery efforts focused on identifying new drugs for tuberculosis, including strains of the virus that have grown resistant to multiple drugs. The Lilly TB Drug Discovery Initiative was started in 2007.

November 8, 2011
Lilly, Amylin terminate diabetes alliance

Eli Lilly and Amylin Pharmaceuticals are ending their diabetes-drug alliance, the two companies said Tuesday.

SAN DIEGO — Eli Lilly and Amylin Pharmaceuticals are ending their diabetes-drug alliance, the two companies said Tuesday.

Indianapolis-based Lilly and San Diego-based Amylin said they would terminate their alliance concerning exenatide, the active ingredient in the injected diabetes drug Byetta and its long-acting version, Bydureon, currently under investigation.

November 7, 2011
FDA gives new approval to Bristol-Myers Squibb's, Lilly's Erbitux

The Food and Drug Administration has approved a drug made by Bristol-Myers Squibb for treating head and neck cancer, the agency said Monday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a drug made by Bristol-Myers Squibb and Eli Lilly & Co. for treating head and neck cancer, the agency said Monday.

The FDA announced the approval of Erbitux (cetuximab) for use with chemotherapy in treating head and neck cancer that had spread to other parts of the body. The drug originally was approved in 2004 for treating certain cases of late-stage colon cancer in patients who had stopped responding to chemotherapy.

October 25, 2011
Lilly removes Xigris from market

Eli Lilly is withdrawing one of its drugs from the market after clinical trials showed it to be ineffective.

INDIANAPOLIS — Eli Lilly is withdrawing one of its drugs from the market after clinical trials showed it to be ineffective.

The drug maker announced Tuesday the withdrawal of Xigris (drotrecogin alfa [activated]) from all markets following results of the "PROWESS-SHOCK" study, which found that it did not produce a statistically significant reduction in 28-day, all-cause death in patients with septic shock. The company said there were no new findings regarding the drug's safety profile.

October 24, 2011
FDA approves generic versions of Zyprexa

The Food and Drug Administration has approved the first generic versions of two drugs made by Eli Lilly for treating schizophrenia and bipolar disorder, the agency said Monday.

SILVER SPRING, Md. — The Food and Drug Administration has approved the first generic versions of two drugs made by Eli Lilly for treating schizophrenia and bipolar disorder, the agency said Monday.

The FDA announced the approval of generic olanzapine tablets and olanzapine orally disintegrating tablets, respectively generic versions of Lilly's Zyprexa and Zyprexa Zydus. Dr. Reddy's Labs and Teva Pharmaceuticals USA will manufacture olanzapine tablets, while Dr. Reddy's, Apotex and Par Pharmaceuticals will manufacture the orally disintegrating version.

October 20, 2011
Byetta approved for use with Lantus

A diabetes drug made by Eli Lilly and Amylin Pharmaceuticals has received approval from the Food and Drug Administration for use with an insulin product made by Sanofi.

INDIANAPOLIS — A diabetes drug made by Eli Lilly and Amylin Pharmaceuticals has received approval from the Food and Drug Administration for use with an insulin product made by Sanofi.

Lilly and Amylin said Byetta (eventide) won approval from the FDA as an add-on therapy for patients with Type 2 diabetes taking Sanofi's Lantus (insulin glargine [rDNA origin]) who have not achieved adequate blood sugar control on Lantus alone.

October 20, 2011
Prasco to market authorized generic Zyprexa

Prasco Labs will make authorized generic versions of two psychiatric drugs made by Eli Lilly under a partnership between the two companies announced Thursday.

CINCINNATI — Prasco Labs will make authorized generic versions of two psychiatric drugs made by Eli Lilly under a partnership between the two companies announced Thursday.

Prasco will market authorized generic versions of Zyprexa (olanzapine) tablets and Zyprexa Zydis orally disintegrating tablets. The drugs are used to treat schizophrenia and bipolar disorder. Financial terms of the deal were not disclosed.

October 12, 2011
Lilly drug effectively treats enlarged prostate, study finds

A drug made by Eli Lilly & Co. produced "significant" improvements in patients with erectile dysfunction who also had benign prostatic hyperplasia, according to results of a new study.

INDIANAPOLIS — A drug made by Eli Lilly & Co. produced "significant" improvements in patients with erectile dysfunction who also had benign prostatic hyperplasia, according to results of a new study.

The phase-3 study, published in the Journal of Sexual Medicine, found that Cialis (tadalafil) improved erectile dysfunction and benign prostatic hyperplasia in men with both conditions. BPH is a condition in which the prostate enlarges, causing urinary symptoms.

October 11, 2011
Lilly announces senior management changes

Two senior leaders at Eli Lilly are retiring, the company said Tuesday.

INDIANAPOLIS — Two senior leaders at Eli Lilly are retiring, the company said Tuesday.

The Indianapolis-based drug maker announced the Dec. 31 retirements of Lilly SVP and Bio-Medicines president Bryce Carmine, and president of manufacturing operations Frank Deane. Carmine and Deane have worked at Lilly for 36 years and 33 years, respectively. Lilly USA president Dave Ricks will replace Carmine, while SVP global drug product manufacturing Maria Crowe will replace Deane.

October 7, 2011
Lilly's Cialis approved for benign prostatic hyperplasia

The Food and Drug Administration has approved a new use for a drug made by Eli Lilly for erectile dysfunction, Lilly said Friday.

INDIANAPOLIS — The Food and Drug Administration has approved a new use for a drug made by Eli Lilly for erectile dysfunction, Lilly said Friday.

The FDA approved Cialis (tadalafil) as a once-daily treatment for men with erectile dysfunction and benign prostatic hyperplasia, also known as BPH, as well as for BPH alone. BPH is a condition in which the prostate enlarges, which can cause urinary symptoms.

September 16, 2011
BI, Lilly drug reduces blood sugar over long term

A drug made by Boehringer Ingelheim and Eli Lilly showed "meaningful and durable" reductions in blood sugar in adults with Type 2 diabetes, according to results of a late-stage clinical trial presented Friday at a conference in Europe.

LISBON, Portugal — A drug made by Boehringer Ingelheim and Eli Lilly showed "meaningful and durable" reductions in blood sugar in adults with Type 2 diabetes, according to results of a late-stage clinical trial presented Friday at a conference in Europe.

September 12, 2011
Studies: Bydureon shows improvements in cardiovascular health

Patients treated with a long-acting drug for Type 2 diabetes experienced a reduction in cardiovascular health risk factors, according to results of a study presented at the European Association for the Study of Diabetes' annual meeting.

LISBON, Portugal — Patients treated with a long-acting drug for Type 2 diabetes experienced a reduction in cardiovascular health risk factors, according to results of a study presented at the European Association for the Study of Diabetes' annual meeting.

August 16, 2011
Study: Effient reduces cardiovascular risk among younger, heavier patient cohort

A special group of patients who participated in a trial of a heart disease drug made by Daiichi Sankyo and Eli Lilly showed fewer heart attacks, strokes and deaths related to cardiovascular disease than patients taking a competing drug, according to an analysis of study results.

INDIANAPOLIS — A special group of patients who participated in a trial of a heart disease drug made by Daiichi Sankyo and Eli Lilly showed fewer heart attacks, strokes and deaths related to cardiovascular disease than patients taking a competing drug, according to an analysis of study results.

July 14, 2011
Eli Lilly & Co., Disney partner to create lifestyle media for families affected by Type 1 diabetes

Eli Lilly & Co. and Disney are collaborating to produce a dedicated lifestyle website and publications for families affected by Type 1 diabetes, the two companies said Thursday.

INDIANAPOLIS — Eli Lilly & Co. and Disney are collaborating to produce a dedicated lifestyle website and publications for families affected by Type 1 diabetes, the two companies said Thursday.

June 9, 2011
Court vacates Amylin restraining order against Eli Lilly

A federal court has ruled in favor of drug maker Eli Lilly & Co. in a dispute with Amylin Pharmaceuticals over Lilly’s partnership with German drug maker Boehringer Ingelheim.

INDIANAPOLIS — A federal court has ruled in favor of drug maker Eli Lilly in a dispute with Amylin Pharmaceuticals over Lilly’s partnership with German drug maker Boehringer Ingelheim.

June 9, 2011
FDA approves labeling change for Eli Lilly insulin product

Patients with Type 1 diabetes using an insulin product made by Eli Lilly can store it in their pumps for longer periods of time, while children using it have additional options, thanks to a labeling change approved Wednesday by the Food and Drug Administration.

INDIANAPOLIS — Patients with Type 1 diabetes using an insulin product made by Eli Lilly can store it in their pumps for longer periods of time, while children using it have additional options, thanks to a labeling change approved Wednesday by the Food and Drug Administration.

December 9, 2010
Combining Lilly and Amylin drug with insulin intake found to promote weight loss

Combining a diabetes drug marketed by Eli Lilly and Amylin Pharmaceuticals controls blood sugar and promotes weight loss more than insulin alone, according to a new study.

CHAPEL HILL, N.C. — Combining a diabetes drug marketed by Eli Lilly and Amylin Pharmaceuticals controls blood sugar and promotes weight loss more than insulin alone, according to a new study.

August 19, 2010
FDA recommends expanding the use of Cymbalta

A Food and Drug Administration advisory committee has voted to recommend expanding the use of...

BETHESDA, Md. A Food and Drug Administration advisory committee has voted to recommend expanding the use of an Eli Lilly & Co. pain drug, the drug maker said Thursday.

Lilly said the FDA’s Anesthetic and Life Support Drugs Advisory Committee voted to recommend approval of Cymbalta (duloxetine hydrochloride) as a treatment for chronic lower back pain, though it did not support the drug as a treatment for chronic pain due to osteoarthritis. The drug currently is approved for treating diabetic peripheral neuropathic pain and fibromyalgia.